tranexamic acid has been researched along with Epistaxis in 71 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Epistaxis: Bleeding from the nose.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with non-traumatic epistaxis were evaluated in three treatment groups as topical lidocaine, epinephrine, and TXA." | 9.51 | Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study. ( Ekmekyapar, M; Gur, A; Sahin, L, 2022) |
| "Intranasal topical application of tranexamic acid is associated with a lower rate of need for anterior nasal packing and a shortened stay in the ED; it may be considered a part of the treatment for atraumatic anterior epistaxis." | 9.51 | Intranasal Topical Application of Tranexamic Acid in Atraumatic Anterior Epistaxis: A Double-Blind Randomized Clinical Trial. ( Asmarian, N; Babaei, A; Faramarzi, A; Hosseinialhashemi, M; Jahangiri, R; Kherad, M; Sajedianfard, S; Soltaniesmaeili, A, 2022) |
| " Participants with spontaneous epistaxis, persisting after simple first aid and the application of a topical vasoconstrictor, were randomly allocated to receive topical tranexamic acid or placebo." | 9.41 | The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial. ( Appelboam, A; Barton, A; Body, R; Coppell, J; Ewings, P; Hilton, M; Ingram, W; Jeffery, AN; Reuben, A; Stevens, KN; Vickery, J; Wainman, B, 2021) |
| "We evaluated the efficacy of topical application of the injectable form of tranexamic acid (TXA) compared with anterior nasal packing (ANP) for the treatment of epistaxis in patients taking antiplatelet drugs (aspirin, clopidogrel, or both) who presented to the emergency department (ED)." | 9.27 | Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. ( Mousavi Jazayeri, MH; Naderi, A; Naderpour, Z; Saeedi, M; Zahed, R, 2018) |
| "Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia." | 9.19 | Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. ( Bieg, B; Geisthoff, UW; König, J; Kübler, M; Plinkert, PK; Seyfert, UT, 2014) |
| "Topical application of injectable form of tranexamic acid (500 mg in 5 mL) was compared with anterior nasal packing in 216 patients with anterior epistaxis presented to an ED in a randomized clinical trial." | 9.17 | A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. ( Alizadeharasi, S; Ghasemi, A; Moharamzadeh, P; Saeedi, M; Zahed, R, 2013) |
| "This study evaluated oral tranexamic acid as an adjunct in controlling epistaxis and preventing or reducing recurrent epistaxis." | 9.06 | Oral tranexamic acid in the management of epistaxis. ( O'Reilly, BF; White, A, 1988) |
| "To compare topical tranexamic acid (TXA) with control groups for the treatment of acute epistaxis assessing bleeding cessation, discharge within 2 hours, rebleeding rates, complication rates, and patient satisfaction." | 9.01 | Topical Tranexamic Acid for the Treatment of Acute Epistaxis: A Systematic Review and Meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD, 2019) |
| "To determine the effects of tranexamic acid (oral, intravenous or topical) compared with placebo, no additional intervention or any other haemostatic agent in the management of patients with epistaxis." | 8.98 | Tranexamic acid for patients with nasal haemorrhage (epistaxis). ( Bellorini, J; Burton, MJ; Joseph, J; Martinez-Devesa, P, 2018) |
| "Topical tranexamic acid may have a role in the treatment of anterior epistaxis in select ED patients, though additional studies are needed to confirm its role in treatment algorithms." | 8.93 | Role of topical tranexamic acid in the management of idiopathic anterior epistaxis in adult patients in the emergency department. ( Logan, JK; Pantle, H, 2016) |
| "A shortcut review was carried out to establish whether tranexamic acid is effective in controlling epistaxis." | 8.93 | BET 1: Tranexamic acid in epistaxis: who bloody nose? ( May, G; Penrose, N, 2016) |
| "The role of tranexamic acid in the management of epistaxis remains unclear." | 8.93 | Tranexamic acid in epistaxis: a systematic review. ( Fox, H; Kamhieh, Y, 2016) |
| "A short-cut review was carried out to establish whether intravenous tranexamic acid is beneficial in managing acute epistaxis." | 8.91 | BET 1: Intravenous tranexamic acid in the treatment of acute epistaxis. ( Fox, H; Hunter, F, 2015) |
| "A short-cut review was carried out to establish whether topical tranexamic acid can be used to treat spontaneous epistaxis." | 8.90 | Best evidence topic reports. BET 3: Topical intranasal tranexamic acid for spontaneous epistaxis. ( Hilton, L; Reuben, A, 2014) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 8.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "This study demonstrated that the topical application of the intravenous preparation of TXA is more effective than topical oxymetazoline for achievement of hemostasis in anterior epistaxis." | 7.96 | Comparative Effectiveness of Topically Administered Tranexamic Acid Versus Topical Oxymetazoline Spray for Achieving Hemostasis in Epistaxis. ( Johnson, J; Schrader, M; Whitworth, K; Wisniewski, S, 2020) |
| "The aim of this study was to develop a nasal powder formulation of the antifibrinolytic drug, tranexamic acid (TXA), in combination with the wound-healing agent hyaluronic acid (HA) for the local treatment of epistaxis (nose bleeding)." | 7.96 | Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. ( Ghadiri, M; Gomes Dos Reis, L; Traini, D; Young, P, 2020) |
| "To evaluate the effectiveness and potential benefits of topical tranexamic acid (TXA) in the management of acute epistaxis." | 7.88 | Topical tranexamic acid for the treatment of acute epistaxis in the emergency department. ( Birmingham, AR; Hansen, M; Mah, ND; Ran, R, 2018) |
| "ABSTRACTClinical questionDoes the addition of topical tranexamic acid to anterior nasal packing decrease bleeding in patients with epistaxis who are taking antiplatelet medications?Article chosenZahed R, Jayazeri M, Naderi A, et al." | 7.88 | Topical tranexamic acid for the treatment of epistaxis in patients using antiplatelet agents. ( Lang, E; Powell, J; Sanderson, M, 2018) |
| " A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial." | 7.83 | Tranexamic Acid for Epistaxis--A Promising Treatment That Deserves Further Study. ( Barbic, D; Clinkard, D, 2016) |
| "Tranexamic acid (TXA) is a cheap, safe, readily available antifibrinolytic agent known to be beneficial in a variety of clinical settings where uncontrolled bleeding may be a problem." | 6.90 | Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol. ( Appelboam, A; Barton, A; Body, R; Coppell, J; Ewings, P; Hilton, M; Reuben, A; Vickery, PJ, 2019) |
| "Epistaxis is a very common presentation in the emergency department (ED), accounting for approximately 1 in 200 ED visits in the United States." | 6.82 | Efficacy of topical tranexamic acid in epistaxis: A systematic review and meta-analysis. ( Janapala, RN; Mehta, E; Patel, J; Pourmand, A; Tran, QK, 2022) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 6.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Spontaneous epistaxis is one of the most frequent problems in emergency services." | 6.58 | Topical tranexamic acid for spontaneous epistaxis. ( Rosenbaum, A; Santander, MJ; Winter, M, 2018) |
| "Patients with non-traumatic epistaxis were evaluated in three treatment groups as topical lidocaine, epinephrine, and TXA." | 5.51 | Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study. ( Ekmekyapar, M; Gur, A; Sahin, L, 2022) |
| "Intranasal topical application of tranexamic acid is associated with a lower rate of need for anterior nasal packing and a shortened stay in the ED; it may be considered a part of the treatment for atraumatic anterior epistaxis." | 5.51 | Intranasal Topical Application of Tranexamic Acid in Atraumatic Anterior Epistaxis: A Double-Blind Randomized Clinical Trial. ( Asmarian, N; Babaei, A; Faramarzi, A; Hosseinialhashemi, M; Jahangiri, R; Kherad, M; Sajedianfard, S; Soltaniesmaeili, A, 2022) |
| "Epistaxis is a well-known problem that is mostly self-limited." | 5.48 | Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED? ( Clemons, P; Hassen, GW; Kalantari, H; Kaplun, M, 2018) |
| "We aimed to evaluate the effectiveness of topical tranexamic acid (TXA) versus topical vasoconstrictors in the management of epistaxis via a systematic review and meta-analysis." | 5.41 | A Systematic Review and Meta-analysis of the Effects of Topical Tranexamic Acid ( Cha, X; Li, F; Li, T; Liang, C; Liu, H; Ren, W; Wang, S; Wang, T; Yan, J; Zhuang, C, 2023) |
| " Participants with spontaneous epistaxis, persisting after simple first aid and the application of a topical vasoconstrictor, were randomly allocated to receive topical tranexamic acid or placebo." | 5.41 | The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial. ( Appelboam, A; Barton, A; Body, R; Coppell, J; Ewings, P; Hilton, M; Ingram, W; Jeffery, AN; Reuben, A; Stevens, KN; Vickery, J; Wainman, B, 2021) |
| "Hereditary hemorrhagic telangiectasia has been underreported for many years." | 5.38 | Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. ( Collins, C; Flanagan, BA; Parra, S, 2012) |
| "The primary objective of this study is to compare the effectiveness of 3 treatment protocols to stop anterior epistaxis: classic compression, nasal packing, and local application of tranexamic acid." | 5.30 | Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial. ( Akkan, S; Aytar, H; Çevik, Y; Çorbacıoğlu, ŞK; Dağar, S; Emektar, E, 2019) |
| "We evaluated the efficacy of topical application of the injectable form of tranexamic acid (TXA) compared with anterior nasal packing (ANP) for the treatment of epistaxis in patients taking antiplatelet drugs (aspirin, clopidogrel, or both) who presented to the emergency department (ED)." | 5.27 | Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. ( Mousavi Jazayeri, MH; Naderi, A; Naderpour, Z; Saeedi, M; Zahed, R, 2018) |
| "Among patients with HHT, there were no significant between-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency." | 5.22 | Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. ( Chakinala, MM; Clancy, MS; Everett, EM; Faughnan, ME; Gossage, JR; James, M; Johnson, MH; McWilliams, JP; Merlo, CA; Oh, SP; Olitsky, SE; Pyeritz, RE; Sautter, NB; Whitehead, KJ, 2016) |
| "Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia." | 5.19 | Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. ( Bieg, B; Geisthoff, UW; König, J; Kübler, M; Plinkert, PK; Seyfert, UT, 2014) |
| "In a self-controlled comparative clinical trial, to offer the best solution to stop epistaxis at home (within 10 minutes), patients with inherited bleeding disorders were treated using three different topical hemostatic agents, including Tranexamic acid impregnated tampon, EpiCell tampon prepared from oxidized regenerated cellulose pad, and ChitoHem tampon (reinforced with chitosan)." | 5.19 | A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. ( Eshghi, P; Habibpanah, B; Jenabzade, A, 2014) |
| "Topical application of injectable form of tranexamic acid (500 mg in 5 mL) was compared with anterior nasal packing in 216 patients with anterior epistaxis presented to an ED in a randomized clinical trial." | 5.17 | A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. ( Alizadeharasi, S; Ghasemi, A; Moharamzadeh, P; Saeedi, M; Zahed, R, 2013) |
| "This study evaluated oral tranexamic acid as an adjunct in controlling epistaxis and preventing or reducing recurrent epistaxis." | 5.06 | Oral tranexamic acid in the management of epistaxis. ( O'Reilly, BF; White, A, 1988) |
| "To compare topical tranexamic acid (TXA) with control groups for the treatment of acute epistaxis assessing bleeding cessation, discharge within 2 hours, rebleeding rates, complication rates, and patient satisfaction." | 5.01 | Topical Tranexamic Acid for the Treatment of Acute Epistaxis: A Systematic Review and Meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD, 2019) |
| "To determine the effects of tranexamic acid (oral, intravenous or topical) compared with placebo, no additional intervention or any other haemostatic agent in the management of patients with epistaxis." | 4.98 | Tranexamic acid for patients with nasal haemorrhage (epistaxis). ( Bellorini, J; Burton, MJ; Joseph, J; Martinez-Devesa, P, 2018) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| "A shortcut review was carried out to establish whether tranexamic acid is effective in controlling epistaxis." | 4.93 | BET 1: Tranexamic acid in epistaxis: who bloody nose? ( May, G; Penrose, N, 2016) |
| "The role of tranexamic acid in the management of epistaxis remains unclear." | 4.93 | Tranexamic acid in epistaxis: a systematic review. ( Fox, H; Kamhieh, Y, 2016) |
| " A PubMED and Cochrane Library search was performed on 10/03/16 using, but not limited to, the search terms epistaxis, nosebleed, nose bleeding, nasal haemorrhage, nasal bleeding AND each of the following search terms: antithrombotic, anticoagulant, antiplatelet, aspirin, clopidogrel, warfarin, dabigatran, rivaroxaban, apixaban and tranexamic acid." | 4.93 | A systematic review of anti-thrombotic therapy in epistaxis. ( Musgrave, KM; Powell, J, 2016) |
| "Topical tranexamic acid may have a role in the treatment of anterior epistaxis in select ED patients, though additional studies are needed to confirm its role in treatment algorithms." | 4.93 | Role of topical tranexamic acid in the management of idiopathic anterior epistaxis in adult patients in the emergency department. ( Logan, JK; Pantle, H, 2016) |
| "A short-cut review was carried out to establish whether intravenous tranexamic acid is beneficial in managing acute epistaxis." | 4.91 | BET 1: Intravenous tranexamic acid in the treatment of acute epistaxis. ( Fox, H; Hunter, F, 2015) |
| "A short-cut review was carried out to establish whether topical tranexamic acid can be used to treat spontaneous epistaxis." | 4.90 | Best evidence topic reports. BET 3: Topical intranasal tranexamic acid for spontaneous epistaxis. ( Hilton, L; Reuben, A, 2014) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 4.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "None of the patients experienced further bleeding following the commencement of tranexamic acid treatment, and no adverse effect was noted." | 4.89 | Treatment of bleeding upper aerodigestive tract tumor-a novel approach with antifibrinolytic agent: case series and literature review. ( Clark, JR; Elliott, M; Huang, J; Low, TH; Reid, C, 2013) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "Patients with recurrent epistaxis, particularly due to hereditary hemorrhagic telangiectasia (HHT) are recommended to apply topical tranexamic acid (TXA) to reduce bleeding events." | 4.02 | Effects of tranexamic acid on human nasal ciliary beat frequency. ( Behr, W; Birk, R; Folz, B; Geisthoff, UW; Horschke, F; Li, H; Mueller, CE; Nastev, A; Sommer, JU; Stuck, BA, 2021) |
| "This study demonstrated that the topical application of the intravenous preparation of TXA is more effective than topical oxymetazoline for achievement of hemostasis in anterior epistaxis." | 3.96 | Comparative Effectiveness of Topically Administered Tranexamic Acid Versus Topical Oxymetazoline Spray for Achieving Hemostasis in Epistaxis. ( Johnson, J; Schrader, M; Whitworth, K; Wisniewski, S, 2020) |
| "The aim of this study was to develop a nasal powder formulation of the antifibrinolytic drug, tranexamic acid (TXA), in combination with the wound-healing agent hyaluronic acid (HA) for the local treatment of epistaxis (nose bleeding)." | 3.96 | Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. ( Ghadiri, M; Gomes Dos Reis, L; Traini, D; Young, P, 2020) |
| "ABSTRACTClinical questionDoes the addition of topical tranexamic acid to anterior nasal packing decrease bleeding in patients with epistaxis who are taking antiplatelet medications?Article chosenZahed R, Jayazeri M, Naderi A, et al." | 3.88 | Topical tranexamic acid for the treatment of epistaxis in patients using antiplatelet agents. ( Lang, E; Powell, J; Sanderson, M, 2018) |
| "To evaluate the effectiveness and potential benefits of topical tranexamic acid (TXA) in the management of acute epistaxis." | 3.88 | Topical tranexamic acid for the treatment of acute epistaxis in the emergency department. ( Birmingham, AR; Hansen, M; Mah, ND; Ran, R, 2018) |
| " A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial." | 3.83 | Tranexamic Acid for Epistaxis--A Promising Treatment That Deserves Further Study. ( Barbic, D; Clinkard, D, 2016) |
| "The anti-fibrinolytic agent tranexamic acid (TXA) has been used to reduce bleeding in patients with hereditary hemorrhagic telangiectasia (HHT); however, there are limited data on its efficacy and safety." | 3.81 | The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey. ( Faughnan, ME; Ravichakaravarthy, T; Shehata, N; Zaffar, N, 2015) |
| "Oral tranexamic acid is useful for achieving significant reductions in epistaxis frequency and intensity in selected patients with HHT." | 3.74 | [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. ( Botella, LM; Fernández, A; Morales-Angulo, C; Pérez del Molino, A; Sanz-Rodríguez, F; Zarrabeitia, R, 2007) |
| "Postoperative epistaxis is a known possibility following endoscopic sinonasal surgery." | 3.30 | Tranexamic acid does not significantly lower postoperative bleeding after endoscopic sinus and nasal surgery. ( Chan, E; Hwang, PH; Khanwalkar, A; Kim, D; Ma, Y; Nayak, JV; Patel, ZM; Roozdar, P, 2023) |
| "Tranexamic acid (TXA) is a cheap, safe, readily available antifibrinolytic agent known to be beneficial in a variety of clinical settings where uncontrolled bleeding may be a problem." | 2.90 | Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol. ( Appelboam, A; Barton, A; Body, R; Coppell, J; Ewings, P; Hilton, M; Reuben, A; Vickery, PJ, 2019) |
| "Nasal bleeding was monitored after surgery and up to 2 weeks postoperatively." | 2.90 | Effect of single-dose intravenous tranexamic acid on postoperative nasal bleed in septoplasty. ( Adeel, M; Akhtar, S; Faraz, Q; Nawaz, A; Zakir, I; Zaman, SU, 2019) |
| "Epistaxis is a very common presentation in the emergency department (ED), accounting for approximately 1 in 200 ED visits in the United States." | 2.82 | Efficacy of topical tranexamic acid in epistaxis: A systematic review and meta-analysis. ( Janapala, RN; Mehta, E; Patel, J; Pourmand, A; Tran, QK, 2022) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 2.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Epistaxis is one of the most common complaints presenting to emergency departments." | 2.61 | Management of idiopathic epistaxis in adults: what's new? ( Cammaroto, G; De Vito, A; Firinu, E; Georgalas, C; Gobbi, R; Meccariello, G; Montevecchi, F; Vicini, C, 2019) |
| "Spontaneous epistaxis is one of the most frequent problems in emergency services." | 2.58 | Topical tranexamic acid for spontaneous epistaxis. ( Rosenbaum, A; Santander, MJ; Winter, M, 2018) |
| "Epistaxis is a well-known problem that is mostly self-limited." | 1.48 | Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED? ( Clemons, P; Hassen, GW; Kalantari, H; Kaplun, M, 2018) |
| "This rare case of hereditary hemorrhagic telangiectasia demonstrates that it occurs in an African population and that diagnostic challenges in resource-limited settings can be surmounted." | 1.43 | Definite hereditary hemorrhagic telangiectasia in a 60-year-old black Kenyan woman: a case report. ( Bloomfield, GS; Kiyeng, JC; Koech, C; Siika, A, 2016) |
| "Hereditary hemorrhagic telangiectasia has been underreported for many years." | 1.38 | Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. ( Collins, C; Flanagan, BA; Parra, S, 2012) |
| "Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT)." | 1.34 | Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. ( Bernabéu, C; Botella, LM; Fernandez-L, A; Garrido-Martin, EM; Morales-Angulo, C; Perez-Molino, A; Ramirez, JR; Sanz-Rodriguez, F; Zarrabeitia, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (14.08) | 29.6817 |
| 2010's | 43 (60.56) | 24.3611 |
| 2020's | 15 (21.13) | 2.80 |
| Authors | Studies |
|---|---|
| Janapala, RN | 1 |
| Tran, QK | 1 |
| Patel, J | 1 |
| Mehta, E | 1 |
| Pourmand, A | 1 |
| Torres, E | 1 |
| Johnson, MY | 1 |
| Seebald, K | 1 |
| Kachhi, P | 1 |
| Ekmekyapar, M | 1 |
| Sahin, L | 1 |
| Gur, A | 1 |
| Hosseinialhashemi, M | 1 |
| Jahangiri, R | 1 |
| Faramarzi, A | 1 |
| Asmarian, N | 1 |
| Sajedianfard, S | 1 |
| Kherad, M | 1 |
| Soltaniesmaeili, A | 1 |
| Babaei, A | 1 |
| Rech, MA | 1 |
| Gottlieb, M | 2 |
| Khanwalkar, A | 1 |
| Chan, E | 1 |
| Roozdar, P | 1 |
| Kim, D | 1 |
| Ma, Y | 1 |
| Hwang, PH | 1 |
| Nayak, JV | 1 |
| Patel, ZM | 1 |
| Li, T | 1 |
| Li, F | 1 |
| Cha, X | 1 |
| Wang, S | 1 |
| Yan, J | 1 |
| Wang, T | 1 |
| Liang, C | 1 |
| Zhuang, C | 1 |
| Ren, W | 1 |
| Liu, H | 1 |
| Rosario, E | 1 |
| Sharma, E | 1 |
| Patel, A | 1 |
| Guvensen, G | 1 |
| Ashroff, R | 1 |
| McClenaghan, F | 1 |
| Hariri, A | 1 |
| Joseph, J | 2 |
| Zehtabchi, S | 1 |
| Eberle, ML | 1 |
| Schechter-Perkins, EM | 1 |
| Altawil, Z | 1 |
| Whitworth, K | 1 |
| Johnson, J | 1 |
| Wisniewski, S | 1 |
| Schrader, M | 1 |
| Joy, SM | 1 |
| Karthikeyan, P | 1 |
| Gomes Dos Reis, L | 1 |
| Ghadiri, M | 1 |
| Young, P | 1 |
| Traini, D | 1 |
| Al-Samkari, H | 1 |
| Behr, W | 1 |
| Horschke, F | 1 |
| Nastev, A | 1 |
| Mueller, CE | 1 |
| Sommer, JU | 1 |
| Folz, B | 1 |
| Li, H | 1 |
| Geisthoff, UW | 2 |
| Stuck, BA | 1 |
| Birk, R | 1 |
| Reuben, A | 3 |
| Appelboam, A | 2 |
| Stevens, KN | 1 |
| Vickery, J | 1 |
| Ewings, P | 2 |
| Ingram, W | 1 |
| Jeffery, AN | 1 |
| Body, R | 2 |
| Hilton, M | 2 |
| Coppell, J | 2 |
| Wainman, B | 1 |
| Barton, A | 2 |
| Penrose, N | 1 |
| May, G | 1 |
| Zahed, R | 2 |
| Mousavi Jazayeri, MH | 1 |
| Naderi, A | 1 |
| Naderpour, Z | 1 |
| Saeedi, M | 2 |
| Williams, A | 1 |
| Biffen, A | 1 |
| Pilkington, N | 1 |
| Arrick, L | 1 |
| Williams, RJ | 1 |
| Smith, ME | 1 |
| Smith, M | 1 |
| Birchall, J | 1 |
| Hassen, GW | 1 |
| Clemons, P | 1 |
| Kaplun, M | 1 |
| Kalantari, H | 1 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 1 |
| Marple, BF | 1 |
| Birmingham, AR | 1 |
| Mah, ND | 1 |
| Ran, R | 1 |
| Hansen, M | 1 |
| Morgenstern, J | 1 |
| Rangarajan, S | 1 |
| Heitz, C | 1 |
| Bond, C | 1 |
| Milne, WK | 1 |
| Heymer, J | 1 |
| Schilling, T | 1 |
| Räpple, D | 1 |
| Hsu, YP | 1 |
| Hsu, CW | 1 |
| Bai, CH | 1 |
| Cheng, SW | 1 |
| Chen, C | 1 |
| Sanderson, M | 1 |
| Powell, J | 2 |
| Lang, E | 1 |
| Santander, MJ | 1 |
| Rosenbaum, A | 1 |
| Winter, M | 1 |
| DeMott, JM | 1 |
| Peksa, GD | 1 |
| Martinez-Devesa, P | 1 |
| Bellorini, J | 1 |
| Burton, MJ | 1 |
| Vickery, PJ | 1 |
| Meccariello, G | 1 |
| Georgalas, C | 1 |
| Montevecchi, F | 1 |
| Cammaroto, G | 1 |
| Gobbi, R | 1 |
| Firinu, E | 1 |
| De Vito, A | 1 |
| Vicini, C | 1 |
| Bridwell, RE | 1 |
| April, MD | 1 |
| Long, B | 1 |
| Reyes-Chicuellar, N | 1 |
| Doddi, NM | 1 |
| Kalro, A | 1 |
| Patel, H | 1 |
| Akkan, S | 1 |
| Çorbacıoğlu, ŞK | 1 |
| Aytar, H | 1 |
| Emektar, E | 1 |
| Dağar, S | 1 |
| Çevik, Y | 1 |
| Sarkar, D | 1 |
| Martinez, J | 1 |
| Zaman, SU | 1 |
| Zakir, I | 1 |
| Faraz, Q | 1 |
| Akhtar, S | 1 |
| Nawaz, A | 1 |
| Adeel, M | 1 |
| Low, TH | 1 |
| Huang, J | 1 |
| Reid, C | 1 |
| Elliott, M | 1 |
| Clark, JR | 1 |
| Lacout, A | 1 |
| Marcy, PY | 1 |
| El Hajjam, M | 1 |
| Lacombe, P | 1 |
| Ker, K | 1 |
| Beecher, D | 1 |
| Roberts, I | 1 |
| Moharamzadeh, P | 1 |
| Alizadeharasi, S | 1 |
| Ghasemi, A | 1 |
| Eshghi, P | 1 |
| Jenabzade, A | 1 |
| Habibpanah, B | 1 |
| Hilton, L | 1 |
| Seyfert, UT | 1 |
| Kübler, M | 1 |
| Bieg, B | 1 |
| Plinkert, PK | 1 |
| König, J | 1 |
| Gaillard, S | 1 |
| Dupuis-Girod, S | 1 |
| Boutitie, F | 1 |
| Rivière, S | 1 |
| Morinière, S | 1 |
| Hatron, PY | 1 |
| Manfredi, G | 1 |
| Kaminsky, P | 1 |
| Capitaine, AL | 1 |
| Roy, P | 1 |
| Gueyffier, F | 1 |
| Plauchu, H | 1 |
| Zaffar, N | 1 |
| Ravichakaravarthy, T | 1 |
| Faughnan, ME | 2 |
| Shehata, N | 1 |
| Jahanshahi, J | 1 |
| Hashemian, F | 1 |
| Pazira, S | 1 |
| Bakhshaei, MH | 1 |
| Farahani, F | 1 |
| Abasi, R | 1 |
| Poorolajal, J | 1 |
| Utkewicz, MD | 1 |
| Brunetti, L | 1 |
| Awad, NI | 1 |
| Clinkard, D | 1 |
| Barbic, D | 1 |
| Fox, H | 2 |
| Hunter, F | 1 |
| Jervis, S | 1 |
| Saunders, T | 1 |
| Belcher, J | 1 |
| Skinner, D | 1 |
| Kamhieh, Y | 1 |
| Kiyeng, JC | 1 |
| Siika, A | 1 |
| Koech, C | 1 |
| Bloomfield, GS | 1 |
| Musgrave, KM | 1 |
| Whitehead, KJ | 1 |
| Sautter, NB | 1 |
| McWilliams, JP | 1 |
| Chakinala, MM | 1 |
| Merlo, CA | 1 |
| Johnson, MH | 1 |
| James, M | 1 |
| Everett, EM | 1 |
| Clancy, MS | 1 |
| Oh, SP | 1 |
| Olitsky, SE | 1 |
| Pyeritz, RE | 1 |
| Gossage, JR | 1 |
| Logan, JK | 1 |
| Pantle, H | 1 |
| Robard, L | 1 |
| Michel, J | 1 |
| Prulière Escabasse, V | 1 |
| Bequignon, E | 1 |
| Vérillaud, B | 1 |
| Malard, O | 1 |
| Crampette, L | 1 |
| Ghosh, K | 2 |
| Melia, L | 1 |
| McGarry, G | 1 |
| Mikhail, S | 1 |
| Kouides, P | 1 |
| Flanagan, BA | 1 |
| Collins, C | 1 |
| Parra, S | 1 |
| Pérez del Molino, A | 2 |
| Zarrabeitia, R | 3 |
| Fernández, A | 2 |
| Botella, LM | 3 |
| Aydinok, Y | 1 |
| Egemen, A | 1 |
| Balkan, C | 1 |
| Fernandez-L, A | 1 |
| Garrido-Martin, EM | 1 |
| Sanz-Rodriguez, F | 2 |
| Ramirez, JR | 1 |
| Morales-Angulo, C | 2 |
| Perez-Molino, A | 1 |
| Bernabéu, C | 1 |
| Trotter, MI | 1 |
| De, R | 1 |
| Drake-Lee, A | 1 |
| Klepfish, A | 1 |
| Berrebi, A | 1 |
| Schattner, A | 1 |
| Sabbà, C | 1 |
| Gallitelli, M | 1 |
| Palasciano, G | 1 |
| Lozano, M | 1 |
| Nilsson, IM | 1 |
| Verstraete, M | 1 |
| White, A | 1 |
| O'Reilly, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
| Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department[NCT02930941] | Phase 4 | 35 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Terminate due to slow enrollment rate.) | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| The Evaluation of Effectiveness of Nasal Compression With Tranexamic Acid Compared to Simple Nasal Compression and Merocel Packing[NCT03360045] | Phase 4 | 135 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis[NCT05774717] | Phase 1 | 60 participants (Anticipated) | Interventional | 2023-04-01 | Recruiting | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty[NCT02569658] | 110 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Role of Tranexamic Acid (TXA) in the Reduction of Post-operative Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty, a Pilot Study.[NCT04902950] | Phase 4 | 9 participants (Actual) | Interventional | 2020-08-17 | Terminated (stopped due to Logistics) | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery[NCT05708690] | Phase 4 | 132 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Randomized Study on the Topical Application of Tranexamic Acid to Wound Bed for Hemostasis in the Setting Granulating Wounds Following Mohs Micrographic Surgery[NCT04541303] | Early Phase 1 | 62 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia[NCT01031992] | Phase 3 | 23 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.[NCT00355108] | Phase 3 | 170 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
| Low-dose Sirolimus for Nosebleeds in HHT: A Phase II Pilot Study[NCT05269849] | Phase 2 | 10 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
| North American Study of Epistaxis in HHT (NOSE)[NCT01408030] | Phase 2 | 123 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 5.03 |
| 1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 4.47 |
| 1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.93 |
| 1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.12 |
| 1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.32 |
| 1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.36 |
| 1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 0.97 |
| 1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PACU | Follow-up visit | Follow-up phone call | |
| 1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
| Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
| 1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
| Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
Length of stay was defined as time from enrollment in study to discharge from the emergency department (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 268 |
| NS Group | 346 |
The number of participants with re-bleeding at 24 Hours was evaluated during follow up phone call (NCT02930941)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 3 |
| NS Group | 9 |
The number of participants with re-bleeding at one week was evaluated during the follow-up phone call (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 2 |
| NS Group | 6 |
Patient reported thromboembolic events during follow-up phone calls at 24 hours and at one week (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 0 |
| NS Group | 0 |
Time to control of bleeding was defined as the time from the start of enrollment and direct pressure and administration of study drug to the resolution of bleeding (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 64 |
| NS Group | 42 |
Patient-reported drug-related adverse events during ED visit (NCT02930941)
Timeframe: during emergency department (ED) visit
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Nasal burning | Nasal irritation | Unpleasant taste | |
| NS Group | 0 | 0 | 0 |
| TXA Group | 2 | 0 | 1 |
Must be diagnosed via ultrasound duplex (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 1 |
Must be diagnosed via CT chest or V/Q lung scan (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Must be diagnosed via CT scan or MRI (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Patients who received a post-op transfusion of pack red blood cells (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Units of pack red blood cells that the patients recieved (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Units of PRBCs (Number) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level. (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid Group | 152.2 |
| Placebo Group | 178.0 |
The number of days that the post surgical drains remain in place after the surgery. When less than 30 cc per drain in a 24-hour period, the participants are to call and schedule drain removal. (NCT04902950)
Timeframe: Up to 56 days post operatively.
| Intervention | Days (Mean) |
|---|---|
| Group 1 | 16 |
| Group 2 | 22 |
Return to the operating room for evacuation post surgical operative hematoma or seroma assessed by clinical evaluation to include palpation for ballotable fluid collection and assessment of skin for a shiny/tight appearance suggestive of an underlying fluid collection. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
Patients will be monitored clinically at each post-operative visit for signs of post-operative hematoma or seroma. Each patient will be evaluated one week, three weeks, and eight weeks following their procedure to assess overall wound healing. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 1 |
Total minutes of bleeding per week (NCT01408030)
Timeframe: 5-12 weeks of active treatment
| Intervention | Total minutes of bleeding per week (Median) |
|---|---|
| Bevacizumab Spray | 23.5 |
| Estriol Spray | 36.5 |
| Tranexamic Acid Spray | 44.5 |
| Placebo Spray | 46 |
Bleeding episodes per week (NCT01408030)
Timeframe: Weeks 5-12 of active treatment phase
| Intervention | Bleeding episodes per week (Median) |
|---|---|
| Bevacizumab Spray | 7.0 |
| Estriol Spray | 8.0 |
| Tranexamic Acid Spray | 7.5 |
| Placebo Spray | 8.0 |
grams/100 ml, assessed at week 12 (NCT01408030)
Timeframe: 12 weeks
| Intervention | gram/100 ml (Median) |
|---|---|
| Bevacizumab Spray | 12.8 |
| Estriol Spray | 13.1 |
| Tranexamic Acid Spray | 11.4 |
| Placebo Spray | 13.8 |
Hoag Epistaxis Severity Score (ESS) is based on 6 nosebleed variables such as frequency and duration which are entered by patients. The ESS has a minimum value of 0 and maximum value of 10, with 10 representing more severe epistaxis. (NCT01408030)
Timeframe: 12 weeks
| Intervention | units on a scale (0-10) (Median) |
|---|---|
| Bevacizumab Spray | 3.54 |
| Estriol Spray | 3.56 |
| Tranexamic Acid Spray | 4.06 |
| Placebo Spray | 3.74 |
Number of participants requiring RBC transfusion during weeks 1-12 (NCT01408030)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Spray | 1 |
| Estriol Spray | 2 |
| Tranexamic Acid Spray | 5 |
| Placebo Spray | 3 |
Treatment failure is defined as the occurrence of one or more of the following during the study: need for nasal surgery or chemical cautery or other new treatment modality to control epistaxis; transfusion of more than 12 units of RBC; severe complications such as acute myocardial infarction, venous thromboembolism, brain hemorrhage; or death (NCT01408030)
Timeframe: Baseline through 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Spray | 2 |
| Estriol Spray | 5 |
| Tranexamic Acid Spray | 0 |
| Placebo Spray | 3 |
24 reviews available for tranexamic acid and Epistaxis
| Article | Year |
|---|---|
Efficacy of topical tranexamic acid in epistaxis: A systematic review and meta-analysis.
Topics: Administration, Topical; Epistaxis; Humans; Randomized Controlled Trials as Topic; Tranexamic Acid; | 2022 |
A Systematic Review and Meta-analysis of the Effects of Topical Tranexamic Acid
Topics: Administration, Topical; Antifibrinolytic Agents; Epistaxis; Humans; Tranexamic Acid; Vasoconstricto | 2023 |
Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care.
Topics: Anemia; Angiogenesis Inhibitors; Anticoagulants; Antifibrinolytic Agents; Clinical Trials as Topic; | 2021 |
BET 1: Tranexamic acid in epistaxis: who bloody nose?
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Humans; | 2016 |
Haematological factors in the management of adult epistaxis: systematic review.
Topics: Adult; Anticoagulants; Blood Transfusion; Epistaxis; Evidence-Based Medicine; Guideline Adherence; H | 2017 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
Topics: Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Female; Humans; Male; Prognosis; Quality of Life; R | 2019 |
Topical tranexamic acid for spontaneous epistaxis.
Topics: Administration, Topical; Antifibrinolytic Agents; Databases, Factual; Epistaxis; Humans; Randomized | 2018 |
Topical Tranexamic Acid for the Treatment of Acute Epistaxis: A Systematic Review and Meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Epistaxis; Humans; Male; Middle Aged; Tranexamic A | 2019 |
Tranexamic acid for patients with nasal haemorrhage (epistaxis).
Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Blood Transfusion; Epinephri | 2018 |
Management of idiopathic epistaxis in adults: what's new?
Topics: Adult; Cautery; Databases, Factual; Drug Combinations; Electrocoagulation; Embolism; Endoscopy; Endo | 2019 |
Does Oral or Topical Tranexamic Acid Control Bleeding From Epistaxis?
Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Epistaxis; Hemorrhage; Human | 2019 |
Treatment of bleeding upper aerodigestive tract tumor-a novel approach with antifibrinolytic agent: case series and literature review.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antifibrinolytic Agents; Carcinoma, Squamous Cell; Ep | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Best evidence topic reports. BET 3: Topical intranasal tranexamic acid for spontaneous epistaxis.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Humans; Male; Middle Aged; Tranexami | 2014 |
BET 1: Intravenous tranexamic acid in the treatment of acute epistaxis.
Topics: Acute Disease; Administration, Intravenous; Antifibrinolytic Agents; Epistaxis; Evidence-Based Emerg | 2015 |
Tranexamic acid in epistaxis: a systematic review.
Topics: Antifibrinolytic Agents; Epistaxis; Humans; Tranexamic Acid | 2016 |
A systematic review of anti-thrombotic therapy in epistaxis.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epist | 2016 |
Role of topical tranexamic acid in the management of idiopathic anterior epistaxis in adult patients in the emergency department.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Disease Management; Emergency Service, Hosp | 2016 |
Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease.
Topics: Antifibrinolytic Agents; Catheter Ablation; Epistaxis; Hemostatic Techniques; Hemostatics; Humans; L | 2017 |
Epistaxis in adults: a clinical review.
Topics: Adult; Age Factors; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Embolization, Therapeutic; Eme | 2008 |
Evidence-based management of epistaxis in adults.
Topics: Administration, Topical; Adult; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Antifibri | 2006 |
Local fibrinolysis as a mechanism for haemorrhage.
Topics: Aminocaproates; Endometrium; Epistaxis; Female; Fibrinolysis; Gastric Juice; Gastrointestinal Hemorr | 1975 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
15 trials available for tranexamic acid and Epistaxis
| Article | Year |
|---|---|
Comparison of the therapeutic efficacy of topical tranexamic acid, epinephrine, and lidocaine in stopping bleeding in non-traumatic epistaxis: a prospective, randomized, double-blind study.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Me | 2022 |
Intranasal Topical Application of Tranexamic Acid in Atraumatic Anterior Epistaxis: A Double-Blind Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Epistaxis; Humans; Iran; Lidocaine; Phenylephri | 2022 |
Tranexamic acid does not significantly lower postoperative bleeding after endoscopic sinus and nasal surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Epistaxis; Humans; Nasal Surgica | 2023 |
The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial.
Topics: Administration, Intranasal; Aged; Antifibrinolytic Agents; Bandages; Double-Blind Method; Emergency | 2021 |
Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Endotamponade; Epistaxis; Female; Humans; Ma | 2018 |
Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol.
Topics: Administration, Intranasal; Administration, Topical; Antifibrinolytic Agents; Double-Blind Method; E | 2019 |
Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Female; Formaldehyde; Hemostatics; Humans; Male; Middle Ag | 2019 |
Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Female; Formaldehyde; Hemostatics; Humans; Male; Middle Ag | 2019 |
Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Female; Formaldehyde; Hemostatics; Humans; Male; Middle Ag | 2019 |
Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Female; Formaldehyde; Hemostatics; Humans; Male; Middle Ag | 2019 |
Effect of single-dose intravenous tranexamic acid on postoperative nasal bleed in septoplasty.
Topics: Adolescent; Adult; Double-Blind Method; Epistaxis; Humans; Infusions, Intravenous; Middle Aged; Nasa | 2019 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies.
Topics: Administration, Topical; Blood Coagulation Disorders, Inherited; Cellulose; Child; Child, Preschool; | 2014 |
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Chronic D | 2014 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Oral tranexamic acid in the management of epistaxis.
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1988 |
32 other studies available for tranexamic acid and Epistaxis
| Article | Year |
|---|---|
Is Tranexamic Acid (TXA) Effective Compared with Anterior Nasal Packing (ANP) in Achieving Cessation of Bleeding in Patients with Anterior Epistaxis?
Topics: Antifibrinolytic Agents; Epistaxis; Gastrointestinal Diseases; Humans; Pharyngeal Diseases; Tranexam | 2022 |
Can't Stop, Won't Stop: The Return of Tranexamic Acid for Epistaxis.
Topics: Epistaxis; Humans; Tranexamic Acid | 2022 |
Use of tranexamic acid-soaked NasoPore® in the emergency department, to reduce epistaxis admissions.
Topics: Adult; Bandages; Emergency Service, Hospital; Epistaxis; Hospitalization; Humans; Retrospective Stud | 2023 |
TXA plus compression and nasal packing did not differ for epistaxis, and both were better than compression alone.
Topics: Epistaxis; Formaldehyde; Humans; Polyvinyl Alcohol; Tranexamic Acid | 2019 |
Topical tranexamic acid (TXA) for the management of a bleeding arteriovenous fistula.
Topics: Administration, Topical; Aged, 80 and over; Antifibrinolytic Agents; Arteriovenous Fistula; Emergenc | 2020 |
Comparative Effectiveness of Topically Administered Tranexamic Acid Versus Topical Oxymetazoline Spray for Achieving Hemostasis in Epistaxis.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Fema | 2020 |
Letter on the article "Effect of single-dose intravenous tranexamic acid on postoperative nasal bleed in septoplasty".
Topics: Epistaxis; Humans; Postoperative Hemorrhage; Rhinoplasty; Tranexamic Acid | 2021 |
Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis.
Topics: Administration, Intranasal; Aerosols; Antifibrinolytic Agents; Cell Line; Drug Combinations; Drug Co | 2020 |
Effects of tranexamic acid on human nasal ciliary beat frequency.
Topics: Cilia; Epistaxis; Epithelial Cells; Humans; Nasal Mucosa; Tranexamic Acid | 2021 |
Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED?
Topics: Administration, Intranasal; Administration, Topical; Antifibrinolytic Agents; Emergency Service, Hos | 2018 |
Topical tranexamic acid for the treatment of acute epistaxis in the emergency department.
Topics: Acute Disease; Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Emergency Service, Hos | 2018 |
Hot Off the Press: Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs.
Topics: Epistaxis; Humans; Platelet Aggregation Inhibitors; Tranexamic Acid | 2018 |
Use of a mucosal atomization device for local application of tranexamic acid in epistaxis.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Humans; Nebulizers and Vaporizers; T | 2018 |
Topical tranexamic acid for the treatment of epistaxis in patients using antiplatelet agents.
Topics: Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Humans; Platelet Aggregation Inhibi | 2018 |
Sphenopalatine Artery Ligation for Life-Threatening Epistaxis in a 4-Year-Old Child With Glanzmann Thrombasthenia.
Topics: Antifibrinolytic Agents; Child, Preschool; Endoscopy; Epistaxis; Factor VIIa; Female; Fluid Therapy; | 2019 |
Use of Atomized Intranasal Tranexamic Acid as an Adjunctive Therapy in Difficult-to-Treat Epistaxis.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Chemotherapy, Adjuvant; Emergency Service, Hosp | 2019 |
Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.
Topics: Antifibrinolytic Agents; Epistaxis; Female; Humans; Telangiectasia, Hereditary Hemorrhagic; Tranexam | 2013 |
The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.
Topics: Aged; Epistaxis; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Retrospective Studies; Surv | 2015 |
Epistaxis complicated by rivaroxaban managed with topical tranexamic acid.
Topics: Administration, Topical; Aged, 80 and over; Antifibrinolytic Agents; Epistaxis; Factor Xa Inhibitors | 2015 |
Tranexamic Acid for Epistaxis--A Promising Treatment That Deserves Further Study.
Topics: Antifibrinolytic Agents; Epistaxis; Female; Humans; Male; Tranexamic Acid | 2016 |
Evaluating three hundred and fifty-two admissions and predictors of re-admissions for epistaxis - is it time to re-evaluate tranexamic acid in epistaxis?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Epistaxis; Female; Hospitalization; Humans; Male; | 2017 |
Definite hereditary hemorrhagic telangiectasia in a 60-year-old black Kenyan woman: a case report.
Topics: Antifibrinolytic Agents; Arteriovenous Fistula; Arteriovenous Malformations; Blood Transfusion; Comp | 2016 |
Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
Topics: Adult; Antifibrinolytic Agents; Cardiomyopathy, Hypertrophic; Colectomy; Colostomy; Embolization, Th | 2008 |
von Willebrand disease in the pediatric and adolescent population.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres | 2010 |
Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Female; Humans; Middle Aged; Telangi | 2012 |
[Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Epistaxis; Humans; Male; Telangiectasia, Hereditar | 2004 |
Menorrhagia due to abnormalities of the platelet function: evaluation of two young patients.
Topics: Adolescent; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Comorbidity; Deamino Arginine Vasopre | 2007 |
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Adult; Aged; Aged, 80 a | 2007 |
[Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Drug Administration Schedule; Epistaxis; Fe | 2007 |
Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Humans; Male; Middle Aged; Telangiec | 2001 |
Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Humans; Male; Telangiectasia, Hereditary Hemorrhagic; Tran | 2001 |
Tranexamic acid in hereditary hemorrhagic telangiectasia.
Topics: Antifibrinolytic Agents; Body Weight; Epistaxis; Humans; Telangiectasia, Hereditary Hemorrhagic; Tra | 2002 |